Determinants of Peritoneal Membrane Function Over Time

Seminars in Nephrology

Volumn 31, Issue 2, 2011, Pages 172-182

  Davies, Simon J ^a,b   Mushahar, Lily ^a,b   Yu, Zanzhe ^a,b   Lambie, Mark ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

Author keywords

Biocompatibility; Fibrosis; Inflammation; Osmotic conductance; Peritonitis; Solute transport; Ultrafiltration failure

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; DIALYSIS FLUID; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ARTICLE; BLOOD FLOW; CYTOKINE PRODUCTION; FIBROSIS; HUMAN; KIDNEY FUNCTION; MEMBRANE DAMAGE; MEMBRANE TRANSPORT; MESENCHYME; MESOTHELIUM; OSMOSIS; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEUM; PERITONEUM FUNCTION; PERITONITIS; PRIORITY JOURNAL; RISK ASSESSMENT; SOLUTE; TRANSPORT KINETICS; ULTRAFILTRATION; VASCULARIZATION;

BIOCOMPATIBLE MATERIALS; GLUCOSE; HUMANS; KIDNEY; MEMBRANES; PERITONEAL DIALYSIS; PERITONEUM; PERITONITIS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952780842     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2011.01.006     Document Type: Article

References (58)

1. Smit W., Schouten N., van den Berg N., Langedijk M.J., Struijk D.G., Krediet R.T. Analysis of the prevalence and causes of ultrafiltration failure during long-term peritoneal dialysis: a cross-sectional study. Perit Dial Int 2004, 24:562-570.
2. Smit W., van Dijk P., Langedijk M.J., Schouten N., van den Berg N., Struijk D.G., et al. Peritoneal function and assessment of reference values using a 3.86% glucose solution. Perit Dial Int 2003, 23:440-449.
3. Brown E.A., Davies S.J., Rutherford P., Meeus F., Borras M., Riegel W., et al. Survival of functionally anuric patients on automated peritoneal dialysis: the European APD Outcome Study. J Am Soc Nephrol 2003, 14:2948-2957.
4. Jansen M.A., Termorshuizen F., Korevaar J.C., Dekker F.W., Boeschoten E., Krediet R.T. Predictors of survival in anuric peritoneal dialysis patients. Kidney Int 2005, 68:1199-1205.
5. Davies S.J., Brown E.A., Reigel W., Clutterbuck E., Heimburger O., Diaz N.V., et al. What is the link between poor ultrafiltration and increased mortality in anuric patients on automated peritoneal dialysis?. Analysis of data from EAPOS. Perit Dial Int 2006, 26:458-465.
6. Lambie M., John B., Mushahar L., Huckvale C., Davies S.J. The peritoneal osmotic conductance is low well before the diagnosis of encapsulating peritoneal sclerosis is made. Kidney Int 2010, 2010:23.
7. Sampimon D.E., Coester A.M., Struijk D.G., Krediet R.T. Time course of peritoneal transport parameters in peritoneal dialysis patients who develop peritoneal sclerosis. Adv Perit Dial 2007, 23:107-111.
8. Sampimon D.E., Coester A.M., Struijk D.G., Krediet R.T. The time course of peritoneal transport parameters in peritoneal dialysis patients who develop encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2010, 2010:21.
9. Williams J.D., Craig K.J., Topley N., Von Ruhland C., Fallon M., Newman G.R., et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002, 13:470-479.
10. Kihm L.P., Wibisono D., Muller-Krebs S., Pfisterer F., Morath C., Gross M.L., et al. RAGE expression in the human peritoneal membrane. Nephrol Dial Transplant 2008, 23:3302-3306.
11. Davies S.J., Brown B., Bryan J., Russell G.I. Clinical evaluation of the peritoneal equilibration test: a population-based study. Nephrol Dial Transplant 1993, 8:64-70.
12. Asghar R.B., Davies S.J. Pathways of fluid transport and reabsorption across the peritoneal membrane. Kidney Int 2008, 73:1048-1053.
13. Rumpsfeld M., McDonald S.P., Purdie D.M., Collins J., Johnson D.W. Predictors of baseline peritoneal transport status in Australian and New Zealand peritoneal dialysis patients. Am J Kidney Dis 2004, 43:492-501.
14. Davies S.J. Mitigating peritoneal membrane characteristics in modern peritoneal dialysis therapy. Kidney Int Suppl 2006, 103:S76-S83.
15. Oh K.H., Moon J.Y., Oh J., Kim S.G., Hwang Y.H., Kim S., et al. Baseline peritoneal solute transport rate is not associated with markers of systemic inflammation or comorbidity in incident Korean peritoneal dialysis patients. Nephrol Dial Transplant 2008, 23:2356-2364.
16. Rodrigues A.S., Almeida M., Fonseca I., Martins M., Carvalho M.J., Silva F., et al. Peritoneal fast transport in incident peritoneal dialysis patients is not consistently associated with systemic inflammation. Nephrol Dial Transplant 2006, 21:763-769.
17. Heaf J.G., Sarac S., Afzal S. A high peritoneal large pore fluid flux causes hypoalbuminaemia and is a risk factor for death in peritoneal dialysis patients. Nephrol Dial Transplant 2005, 20:2194-2201.
18. Van Biesen W., Van der Tol A., Veys N., Dequidt C., Vijt D., Lamiere N.H., et al. The Personal Dialysis Capacity Test is superior to the peritoneal equilibration test to discriminate inflammation as the cause of fast transport status in peritoneal dialysis patients. Clin J Am Soc Nephrol 2006, 1:269-274.
19. Perl J., Huckvale K., Chellar M., John B., Davies S.J. Peritoneal protein clearance and not peritoneal membrane transport status predicts survival in a contemporary cohort of peritoneal dialysis patients. Clin J Am Soc Nephrol 2009, 4:121-126.
20. Kawanishi H., Shintaku S., Shishida M., Morrishi M., Tsuchiya S., Dohi K. A case of encapsulating peritoneal sclerosis suspected to result from the use of icodextrin peritoneal solution. Adv Perit Dial 2009, 25:45-49.
21. Pecoits-Filho R., Carvalho M.J., Stenvinkel P., Lindholm B., Heimburger O. Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int 2006, 26:53-63.
22. Oh K.H., Jung J.Y., Yoon M.O., Song A., Lee H., Ro H., et al. Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients. Nephrol Dial Transplant 2010, 25:1639-1646.
23. Gillerot G., Goffin E., Michel C., Evenepoel P., Biesen W.V., Tintillier M., et al. Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. Kidney Int 2005, 67:2477-2487.
24. Hwang Y.H., Son M.J., Yang J., Kim K., Chung W., Joo K.W., et al. Effects of interleukin-6 T15A single nucleotide polymorphism on baseline peritoneal solute transport rate in incident peritoneal dialysis patients. Perit Dial Int 2009, 29:81-88.
25. Devuyst O., Yool A.J. Aquaporin-1: new developments and perspectives for peritoneal dialysis. Perit Dial Int 2010, 30:135-141.
26. Davies S.J. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 2004, 66:2437-2445.
27. Mateijsen M.A., van der Wal A.C., Hendriks P.M., Zweers M.M., Mulder J., Struijk D.G., et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999, 19:517-525.
28. Williams J.D., Craig K.J., von Ruhland C., Topley N., Williams G.T. The natural course of peritoneal membrane biology during peritoneal dialysis. Kidney Int Suppl 2003, 88:S43-S49.
29. Honda K., Nitta K., Horita S., Yumura W., Nihei H. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 1996, 72:171-176.
30. Parikova A., Smit W., Struijk D.G., Krediet R.T. Analysis of fluid transport pathways and their determinants in peritoneal dialysis patients with ultrafiltration failure. Kidney Int 2006, 70:1988-1994.
31. Rippe B., Venturoli D. Simulations of osmotic ultrafiltration failure in CAPD using a serial three-pore membrane/fiber matrix model. Am J Physiol Renal Physiol 2007, 292:F1035-F1043.
32. Kawaguchi Y., Kawanishi H., Mujais S., Topley N., Oreopoulos D.G. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000, 20(Suppl 4):S43-S55.
33. Brown M.C., Simpson K., Kerssens J.J., Mactier R.A. Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. Clin J Am Soc Nephrol 2009, 4:1222-1229.
34. Johnson D.W., Cho Y., Livingston B.E., Hawley C.M., McDonald S.P., Brown F.G., et al. Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney Int 2010, 77:904-912.
35. Habib A.M., Preston E., Davenport A. Risk factors for developing encapsulating peritoneal sclerosis in the icodextrin era of peritoneal dialysis prescription. Nephrol Dial Transplant 2010, 25:1633-1638.
36. Davies S.J., Bryan J., Phillips L., Russell G.I. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996, 11:498-506.
37. Evans D.W., Ryckelynck J.P., Fabre E., Verger C. Peritonitis-free survival in peritoneal dialysis: an update taking competing risks into account. Nephrol Dial Transplant 2010, 25:2315-2322.
38. Davies S.J., Phillips L., Naish P.F., Russell G.I. Peritoneal glucose exposure and changes in membrane solute transport with time on Peritoneal Dialysis. J Am Soc Nephrol 2001, 12:1046-1051.
39. Davies S.J., Brown E.A., Frandsen N.E., Rodrigues A.S., Rodriguez-Carmona A., Vychytil A., et al. Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 2005, 67:1609-1615.
40. Yanez-Mo M., Lara-Pezzi E., Selgas R., Ramirez-Huesca M., Dominguez-Jimenez C., Jimenez-Heffernan J.A., et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003, 348:403-413.
41. Del Peso G., Jimenez-Heffernan J.A., Bajo M.A., Aroeira L.S., Aguilera A., Fernandez-Perpen A., et al. Epithelial-to-mesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport. Kidney Int Suppl 2008, 108:S26-S33.
42. Ebinc F.A., Derici U., Gonen S., Reis K.A., Erten Y., Bali M., et al. TGF-beta1 gene polymorphisms and peritoneal equilibration test results in CAPD patients. Ren Fail 2008, 30:15-19.
43. Do J.Y., Kim Y.L., Park J.W., Chang K.A., Lee S.H., Ryu D.H., et al. The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis. Perit Dial Int 2008, 28(Suppl 3):S101-S106.
44. Krediet R.T., Sampimon D.E., Vlijm A., Coester A.M., Struijk D.G., Smit W. Biological markers in the peritoneal dialysate effluent: are they useful. Contrib Nephrol 2009, 163:54-59.
45. Sampimon D.E., Korte M.R., Barreto D.L., Vlijm A., de Waart R., Struijk D.G., et al. Early diagnostic markers for encapsulating peritoneal sclerosis: a case-control study. Perit Dial Int 2010, 30:163-169.
46. Rippe B., Simonsen O., Heimburger O., Christensson A., Haraldsson B., Stelin G., et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001, 59:348-357.
47. Jones S., Holmes C.J., Krediet R.T., MacKenzie R., Faict D., Tranaeus A., et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001, 59:1529-1538.
48. Williams J.D., Topley N., Craig K.J., Mackenzie R.K., Pischetsrieder M., Lage C., et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004, 66:408-418.
49. Bajo M.A., Perez-Lozano M.L., Albar-Vizcaino P., Del Peso G., Castro M.J., Gonzalez-Mateo G., et al. Low-GDP peritoneal dialysis fluid ('balance') has less impact in vitro and ex vivo on epithelial-to-mesenchymal transition (EMT) of mesothelial cells than a standard fluid. Nephrol Dial Transplant 2011, 26:282-291.
50. Davies S.J. Preserving residual renal function in peritoneal dialysis: volume or biocompatibility?. Nephrol Dial Transplant 2009, 24:2620-2622.
51. le Poole C.Y., Welten A.G., Weijmer M.C., Valentijn R.M., van Ittersum F.J., ter Wee P.M. Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious. Perit Dial Int 2005, 25(Suppl 3):S64-S68.
52. Kim S.G., Kim S., Hwang Y.H., Kim K., Oh J.E., Chung W., et al. Could solutions low in glucose degradation products preserve residual renal function in incident peritoneal dialysis patients?. A 1-year multicenter prospective randomized controlled trial (Balnet Study). Perit Dial Int 2008, 28(Suppl 3):S117-S122.
53. Kim S., Oh J., Chung W., Ahn C., Kim S.G., Oh K.H. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrol Dial Transplant 2009, 24:2899-2908.
54. Topley N., Jorres A., Luttmann W., Petersen M.M., Lang M.J., Thierauch K.H., et al. Human peritoneal mesothelial cells synthesize interleukin-6: induction by IL-1 beta and TNF alpha. Kidney Int 1993, 43:226-233.
55. Martikainen T.A., Teppo A.M., Gronhagen-Riska C., Ekstrand A.V. Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane?. Perit Dial Int 2005, 25:453-460.
56. Lee H.Y., Park H.C., Seo B.J., Do J.Y., Yun S.R., Song H.Y., et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005, 25:248-255.
57. Han S.H., Ahn S.V., Yun J.Y., Tranaeus A., Han D.S. Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solutions. Am J Kidney Dis 2009, 54:711-720.
58. Moriishi M., Kawanishi H. Icodextrin and intraperitoneal inflammation. Perit Dial Int 2008, 28(Suppl 3):S96-S100.